Glucagon like Peptide 1 News and Research

RSS

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

9 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.

27 Aug 2024

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion

27 Aug 2024

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Researchers discuss the role of enhanced visceral adipose tissue metabolism in mediating weight loss by glucagon-like peptide-1 drugs.

26 Aug 2024

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Researchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.

26 Aug 2024

Understanding the health benefits of polyphenols through bitter taste receptors

Bioactive compounds like polyphenols and their health benefits have long captured public attention and interest.

23 Aug 2024

New research challenges belief that weight loss drugs only reduce appetite

A study carried out in St Vincent's University Hospital (SVUH) Dublin challenges the belief that weight loss medications such as Ozempic, Wegovy or Monjaro work just by promoting satiety and making you eat less.

22 Aug 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

Gut microbiota plays a crucial role in type 2 diabetes management

Research reveals the intricate role of gut microbiota in type 2 diabetes, highlighting personalized therapeutic strategies and the complexity of microbial interactions with antidiabetic drugs.

15 Aug 2024

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially replacing bariatric surgery for obesity treatment.

28 Jul 2024

How diet affects metabolism and the gut microbiome

In a recent review, researchers explored advances in molecular nutrition, focusing on pharmaceutical and dietary interventions for energy balance and their interactions with the gut microbiome. They also discussed emerging dietary patterns and the implications of microbiome research on nutrition.

28 Jul 2024

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)-;prescription medications sold under popular drug names like Ozempic and Wegovy-;in the United States.

22 Jul 2024

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.

18 Jul 2024

Glucagon like Peptide 1 News and Research

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

ESC consensus statement highlights obesity's impact on cardiovascular disease

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Understanding the health benefits of polyphenols through bitter taste receptors

New research challenges belief that weight loss drugs only reduce appetite

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Gut microbiota plays a crucial role in type 2 diabetes management

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

How diet affects metabolism and the gut microbiome

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News